Heartflow (Nasdaq: HTFL) said a 1,105-patient randomised trial found that CT-guided heart stent planning matched intravascular ultrasound (IVUS) on one-year outcomes. The P4 results were presented at the TCT symposium on November 1, 2026, and published in the New England Journal of Medicine. Target-vessel failure at 12 months was 4.1% with CT guidance versus 4.6% with IVUS. Median procedure time fell from 63 to 46 minutes, and contrast volume dropped about 12%. A separate 203-patient registry, NAVIGATE-PCI, found doctors changed treatment plans in about 70% of cases after using Heartflow's PCI Navigator tool. Stent length was the most common change, at 41%.

Boston Scientific lowers 2026 outlook, partners with Heartflow on PCI. The medtech firm revises its annual guidance amid ongoing recovery from a cyber incident and announces a collaboration to support CT-guided PCI. October 28, 2026 Associate Editor Boston Scientific and Heartflow have announced a strategic collaboration to advance CT-guided planning for percutaneous coronary intervention (PCI) in patients with coronary artery disease. The companies will evaluate compatibility between Heartflow's AI-powered PCI Navigator platform, which creates patient-specific 3D coronary models for preprocedural planning, and Boston Scientific's AVVIGO+ multi-modality guidance system, which supports intravascular imaging and physiology assessment during procedures. They'll also explore ways to integrate the technologies to help physicians plan and perform PCI with greater precision and efficiency. "Through this collaboration, we aim to support more informed clinical decision-making and advance a more personalized approach to care for patients with coronary artery disease, from diagnosis through treatment," Heartflow said in an X post announcing the partnership. The collaboration was also revealed in Boston Scientific's Q3 earnings release. Q3 results and 2026 outlook. Boston Scientific reported $5.14 billion in third-quarter 2026 sales, up 1.5% from the same period last year, as a cybersecurity incident disrupted operations and weighed on results. The company lowered its full-year 2026 sales growth outlook to about 4.25% on a reported basis and 3.75% organically. It expects fourth-quarter sales to decline 1% to 3% year over year, and forecasts adjusted earnings of $0.77 to $0.79 per share. The company posted adjusted earnings of $0.73 per share, down from $0.75 a year earlier. The company estimated the cyber incident stifled organic sales growth by approximately 300 basis points, following an eight-business-day disruption that halted manufacturing and shipments across its global network. Cardiovascular sales grew 1.9% to $3.41 billion, while MedSurg sales increased 0.6% to $1.73 billion. Neuromodulation led growth within MedSurg, with sales rising 13% to $331 million. Endoscopy sales declined 0.6% to $741 million, and Urology sales fell 3.1% to $661 million. During the quarter, Boston Scientific received FDA 510(k) clearance for two technologies in its StoneSmart kidney stone treatment portfolio: the Navigator Flex ureteral access sheath set, which uses suction to remove stone debris, and the LithoVue Elite single-use digital flexible ureteroscope, which adds real-time fluid temperature monitoring. The company also received clearance for an expanded size offering of its SEISMIQ intravascular lithotripsy catheter for treating severely calcified peripheral artery disease. In Q2, Boston Scientific reported initiation of a restructuring plan, for which it expects to make headcount reductions. Add Mpo Mag as a preferred source on Google. Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.